KD5005 / Shanghai Kanda Biotech, Celgen Biopharma - LARVOL DELTA

KD5005: HER-2 dependent strong potent anti-tumor activity of an anti-HER-2 mAb-TNFaimmunocytokine (AACR 2024) - "To address these challenges, we developed KD5005, a novel HER-2-targeted immunocytokine fusion protein comprising an anti-HER-2 IgG1 monoclonal antibody (trastuzumab) and human TNFα. In summary, we have developed KD5005, a HER-2-targeted immunocytokine fusion protein with enhanced tumor-killing activity, improved pharmacokinetic properties, and a favorable toxicity profile. These preclinical findings support the further clinical development of KD5005 as a promising therapeutic agent for HER-2-positive cancers."

Gastric Cancer • Gastrointestinal Cancer • Melanoma • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • TNFA